You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 63 No. 1, January 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (15)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Depression
 •Suicide
 •Genetics
 •Genetic Counseling/ Testing/ Therapy
 •Alert me on articles by topic

Implication of SSAT by Gene Expression and Genetic Variation in Suicide and Major Depression

Adolfo Sequeira, MSc; Fuad G. Gwadry, PhD; Jarlath M. H. ffrench-Mullen, PhD; Lilian Canetti; Yves Gingras, MSc; Robert A. Casero, Jr, PhD; Guy Rouleau, MD, PhD; Chawki Benkelfat, MD; Gustavo Turecki, MD, PhD

Arch Gen Psychiatry. 2006;63:35-48.

Context  A large body of evidence suggests that predisposition to suicide, an important public health problem, is mediated to a certain extent by neurobiological factors.

Objective  To investigate patterns of expression in suicide with and without major depression and to identify new molecular targets that may play a role in the neurobiology of these conditions.

Design  Brain gene expression analysis was performed using the Affymetrix HG-U133 chipset in the orbital cortex (Brodmann area [BA] 11), the dorsolateral prefrontal cortex (BA8/9), and motor cortex (BA4). Subsequent studies were carried out in independent samples from adjacent areas to validate positive findings, confirm their relevance at the protein level, and investigate possible effects of genetic variation.

Subjects  We investigated 12 psychiatrically normal control subjects and 24 suicide victims, including 16 with and 8 without major depression, in the brain gene expression analysis, validation, and protein studies. The genetic studies included 181 suicide completers and 80 psychiatrically normal controls. All subjects investigated were male and of French Canadian origin.

Main Outcome Measures  Gene expression measures from microarray, semiquantitative reverse transcription–polymerase chain reaction, immunohistochemistry, and Western blot analyses.

Results  Twenty-six genes were selected because of the consistency of their expression pattern (fold change, >1.3 in either direction [P≤.01] in at least 2 regions). The spermine/spermidine N1-acetyltransferase gene (SSAT) was successfully validated by reverse transcription–polymerase chain reaction, immunohistochemistry, and Western blot analyses. A variant located in the SSAT polyamine-responsive element regulatory region (SSAT342A/C) demonstrated a significant effect of genotype on SSAT brain expression levels (F1 = 5.34; P = .02). Further investigation of this variant in an independent sample of 181 male suicide completers and 80 male controls showed a higher frequency of the SSAT342C allele among suicide cases (odds ratio, 2.7; 95% confidence interval, 1.4-5.3; P = .005), suggesting that this allele may increase predisposition to suicide.

Conclusions  These data suggest a role for SSAT, the rate-limiting enzyme in the catabolism of polyamines, in suicide and depression and a role for the SSAT342 locus in the regulation of SSAT gene expression.


Author Affiliations: McGill Group for Suicide Studies, Douglas Hospital, McGill University, Montreal, Quebec (Messrs Sequeira and Gingras, Ms Canetti, and Drs Rouleau, Benkelfat, and Turecki); Gene Logic Inc, Gaithersburg, Md (Drs Gwadry and ffrench-Mullen); and The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins School of Medicine, Baltimore, Md (Dr Casero).



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Spermidine/spermine-N1-acetyltransferase: a key metabolic regulator
Pegg
Am. J. Physiol. Endocrinol. Metab. 2008;294:E995-E1010.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.